EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypoxic Preconditioning Enhances the Potential of Mesenchymal Stem Cells to Treat Neonatal Hypoxic-Ischemic Brain Injury

Sara T De Palma, Eva C Hermans, Tatiana M Shamorkina iD, Chloe Trayford iD, Sabine van Rijt iD, Albert J R Heck iD, Cora H A Nijboer iD, Caroline G M de Theije iD

Stroke · 2025-07 · 56 (7) · 1872-1882

DOI: 10.1161/strokeaha.124.048964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke, 2025-07. Verfasst von Sara T De Palma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital (S.T.D.P., E.C.H.,…. Hauptthemen laut MEDLINE: Hypoxia-Ischemia, Brain, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Ischemic Preconditioning. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neonatal hypoxic-ischemic (HI) brain injury is one of the leading causes of long-term neurological morbidity in newborns. Current treatment options for HI brain injury are limited, but mesenchymal stem cell (MSC) therapy is a promising strategy to boost neuroregeneration after injury. Optimization strategies to further enhance the potential of MSCs are under development. The current study aimed to test the potency of hypoxic preconditioning of MSCs to enhance the therapeutic efficacy in a mouse model of neonatal HI injury. METHODS: HI was induced on postnatal day 9 in C57Bl/6 mouse pups. MSCs were cultured under hypoxic (hypoxic-preconditioned MSCs [HP-MSCs], 1% O 2 ) or normoxic-control (normoxic-preconditioned MSCs [NP-MSCs], 21% O 2 ) conditions for 24 hours before use. At 10 days after HI, HP-MSCs, NP-MSCs, or vehicle were intranasally administered. Gold nanoparticle–labeled MSCs were used to assess MSC migration 24 hours after intranasal administration. At 28 days post-HI, lesion size, sensorimotor outcome, and neuroinflammation were assessed by hematoxylin and eosin staining, cylinder rearing task, and ionized calcium-binding adapter molecule 1 (IBA1) staining, respectively. In vitro, the effect of HP-MSCs was studied on transwell migration, neural stem cell differentiation and microglia activation, and the MSC intracellular proteomic content was profiled using quantitative Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). RESULTS: Intranasally administered HP-MSCs were superior to NP-MSCs in reducing lesion size and sensorimotor impairments post-HI. Moreover, hypoxic preconditioning enhanced MSC migration in an in vitro set-up, and in vivo to the lesioned hemisphere after intranasal application. In addition, HP-MSCs enhanced neural stem cell differentiation into more complex neurons in vitro but had similar anti-inflammatory effects compared with NP-MSCs. Lastly, hypoxic preconditioning led to elevated abundances of proteins in MSCs related to extracellular matrix remodeling. CONCLUSIONS: This study shows for the first time that hypoxic preconditioning enhanced the therapeutic efficacy of MSC therapy in a mouse model of neonatal HI brain injury by increasing the migratory and neuroregenerative capacity of MSCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoxia-Ischemia, BrainMesenchymal Stem Cell TransplantationMesenchymal Stem CellsIschemic PreconditioningAnimalsMiceMice, Inbred C57BLAnimals, NewbornDisease Models, AnimalMale

Stichwörter der Autor:innen

brain injurieshypoxia-ischemia, brainmesenchymal stem cellsneonateneurogenesisproteomics

Autor:innen und Institutionen

  • Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital (S.T.D.P., E.C.H., C.H.A.N., C.G.M.d.T.), Utrecht University, the Netherlands.
  • Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, (T.M.S., A.J.R.H.), Utrecht University, the Netherlands.
  • Netherlands Proteomics Center, Utrecht, the Netherlands (T.M.S., A.J.R.H.).
  • Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, the Netherlands (C.T., S.v.R.).

ORCID-Profile: Tatiana M Shamorkina, Chloe Trayford, Sabine van Rijt, Albert J R Heck, Cora H A Nijboer, Caroline G M de Theije

Zitieren

APA

De Palma, S. T., Hermans, E. C., Shamorkina, T. M., Trayford, C., van Rijt, S., Heck, A. J. R., Nijboer, C. H. A., & de Theije, C. G. M. (2025). Hypoxic Preconditioning Enhances the Potential of Mesenchymal Stem Cells to Treat Neonatal Hypoxic-Ischemic Brain Injury. Stroke, 56(7), 1872-1882. https://doi.org/10.1161/strokeaha.124.048964

Vancouver

De Palma ST, Hermans EC, Shamorkina TM, Trayford C, van Rijt S, Heck AJR, et al. Hypoxic Preconditioning Enhances the Potential of Mesenchymal Stem Cells to Treat Neonatal Hypoxic-Ischemic Brain Injury. Stroke. 2025;56(7):1872-1882. doi:10.1161/strokeaha.124.048964

BibTeX
@article{DePalma2025,
  author = {De Palma, Sara T and Hermans, Eva C and Shamorkina, Tatiana M and Trayford, Chloe and van Rijt, Sabine and Heck, Albert J R and Nijboer, Cora H A and de Theije, Caroline G M},
  title = {Hypoxic Preconditioning Enhances the Potential of Mesenchymal Stem Cells to Treat Neonatal Hypoxic-Ischemic Brain Injury},
  journal = {Stroke},
  year = {2025},
  volume = {56},
  number = {7},
  pages = {1872--1882},
  doi = {10.1161/strokeaha.124.048964}
}
Kostenlos starten →